Management ChangeApr 7, 2026, 04:06 PM
Collegium Pharmaceutical Nominates Michael Donovan to Board, Dr. John Fallon to Retire After 10 Years of Service
AI Summary
Collegium Pharmaceutical, Inc. announced a planned board refreshment, nominating Michael Donovan for election at its 2026 Annual Meeting of Shareholders. Mr. Donovan, a Certified Public Accountant with over 36 years of experience, brings extensive financial and life sciences expertise from his tenure as an audit Partner at Ernst & Young LLP. Concurrently, Dr. John Fallon, who has served on the Board since 2016, will retire and not stand for re-election, a decision stated to be part of the Board's ongoing succession planning rather than any disagreement. These changes aim to enhance the Board's financial acumen and strategic oversight.
Key Highlights
- Michael Donovan, 60, has been nominated to stand for election to Collegium Pharmaceutical's Board of Directors at the 2026 Annual Meeting.
- Mr. Donovan has served as an audit Partner at Ernst & Young LLP since 2002 and brings over 36 years of business, accounting, and financial experience in the life sciences industry.
- His leadership roles at EY included Office Managing Partner of EY’s biotechnology office from 2014 to 2024 and East Region Biotechnology Leader.
- John Fallon, M.D., a current director, will retire from the Board at the 2026 Annual Meeting, having served since 2016.
- Dr. Fallon's decision not to seek re-election is part of the Board’s continued focus on board refreshment and succession planning.
Price Impact
More from COLL